Table 3.

Characteristics of the study population, according to the occurrence or not of overall new PCI (for restenosis and de novo IHD) (n = 54)

Parameter	Univariate analysis			Multivariate analysis
	Overall new PCI		p	OR [95% CI]	p
	Yes (n = 8)	No (n = 46)
Age (years), median [IQR]	59.5 [58–60.7]	60.5 [57.7–63]	0.590
Sex, no. (%)			0.380
M	6 (75)	40 (87)
F	2 (25)	6 (13)
BMI, kg/m2, median [IQR]	26.7 [24.8–28.8]	27 [25.8–28]	1.000
Blood pressure (mmHg), median [IQR]
Systolic	125 [120–130]	130 [120–136.2]	0.296
Diastolic	80 [72.5–80]	80 [70–80]	0.574
Hypertension, no. (%)	1 (14)	14 (30)	0.296
Smoke, no. (%)	7 (88)	36 (78)	0.549
Cholesterol (mg/dL), median [IQR]
Total	173.5 [147.5–209.7]	172.5 [146.2–189]	0.658
HDL	44 [34.2–64.5]	42 [35–51]	0.590
LDL	107.5 [86–123.7]	105 [70.2–119.7]	0.765
Triglycerides (mg/dL), median [IQR]	127.5 [117.2–157.7]	127 [102.7–151.5]	0.495
Glycemia (mg/dL), median [IQR]
Baseline	95.5 [86.2–97.7]	86.5 [79.7–89.2]	0.015	0.643 [0.389–1.064]	0.086
2 h	132 [116–136.7]	102.5 [93–121.2]
Glycated hemoglobin (%), median [IQR]	5.6 [5.5–5.7]	5.2 [5–5.4]	0.001
Insulin (µU/mL), median [IQR]	9.8 [9.1–10.1]	3.5 [2.8–4.3]	0.000	0.008 [0.000–1.183]	0.058
HOMA IR, median [IQR]	2.23 [2.1–2.5]	0.74 [0.57–0.94]	0.000	1.5*1011 [2.593–8.68 * 1021]	0.042
Creatinine (mg/dL), median [IQR]	1 [0.85–1.1]	1 [0.87–1.1]	0.971
Hemoglobin (mg/dL), median [IQR]	14.2 [13.2–14.8]	14.3 [13.3–15.3]	0.495
Adiponectin (µg/mL), median [IQR]	8 [6.5–8.7]	12 [10–14]	0.000	0.206 [0.053–0.796]	0.022
Resistin (ng/mL), median [IQR]	13 [6–15]	6 [4–8]	0.013
TNF-alpha (ng/mL), median [IQR]	13 [7.5–20.7]	8 [7–10]	0.073
Follow-up duration (months), median [IQR]	31 [25.7–33.7]	29 [13.5–34]	0.558
Death, no. (%)
Cardiovascular/other causes	0 (−)/−	0 (−)/1 (2)	0.674